Loading…

Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial

Aim To investigate whether previous physical activity levels are associated with blood glucose levels in individuals with impaired glucose tolerance in the context of an international pharmaceutical trial. Methods Data were analysed from the NAVIGATOR trial, which involved 9306 individuals with impa...

Full description

Saved in:
Bibliographic Details
Published in:Diabetic medicine 2015-08, Vol.32 (8), p.1090-1096
Main Authors: Yates, T., Davies, M. J., Haffner, S. M., Schulte, P. J., Thomas, L., Huffman, K. M., Bales, C. W., Preiss, D., Califf, R. M., Holman, R. R., McMurray, J. J. V., Bethel, M. A., Tuomilehto, J., Kraus, W. E.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5952-de0b733b163e2dd051b019c1f29e7a6dc006c0bada49d6e06a6be7e4fa4de9783
cites cdi_FETCH-LOGICAL-c5952-de0b733b163e2dd051b019c1f29e7a6dc006c0bada49d6e06a6be7e4fa4de9783
container_end_page 1096
container_issue 8
container_start_page 1090
container_title Diabetic medicine
container_volume 32
creator Yates, T.
Davies, M. J.
Haffner, S. M.
Schulte, P. J.
Thomas, L.
Huffman, K. M.
Bales, C. W.
Preiss, D.
Califf, R. M.
Holman, R. R.
McMurray, J. J. V.
Bethel, M. A.
Tuomilehto, J.
Kraus, W. E.
description Aim To investigate whether previous physical activity levels are associated with blood glucose levels in individuals with impaired glucose tolerance in the context of an international pharmaceutical trial. Methods Data were analysed from the NAVIGATOR trial, which involved 9306 individuals with impaired glucose tolerance and high cardiovascular risk from 40 different countries, recruited in the period 2002–2004. Fasting glucose, 2‐h post‐challenge glucose and physical activity (pedometer) were assessed annually. A longitudinal regression analysis was used to determine whether physical activity levels 2 years (t‐2) and 1 year (t‐1) previously were associated with levels of glucose, after adjusting for previous glucose levels and other patient characteristics. Those participants with four consecutive annual measures of glucose and two consecutive measures of physical activity were included in the analysis. Results The analysis included 3964 individuals. Change in physical activity from t‐2 to t‐1 and activity levels at t‐2 were both associated with 2‐h glucose levels after adjustment for previous glucose levels and baseline characteristics; however, the associations were weak: a 100% increase in physical activity was associated with a 0.9% reduction in 2‐h glucose levels. In addition, previous physical activity only explained an additional 0.05% of the variance in 2‐h glucose over the variance explained by the history of 2‐h glucose alone (R2 = 0.3473 vs. 0.3468). There was no association with fasting glucose. Conclusions In the context of a large international clinical trial, previous physical activity levels did not meaningfully influence glucose levels in those with a high risk of chronic disease, after taking into account participants' previous trajectory of glucose control. What's new? This is the first study to investigate the prospective relationship of daily step count, as measured by a pedometer, with fasting and 2‐h post‐challenge glucose in an international clinical trial. Recent history of physical activity was weakly related to 2‐h glucose in those with a high risk of Type 2 diabetes after taking into account the trajectory of 2‐h glucose established in the preceding 3 years. A 100% increase in daily step count was associated with a 0.9% reduction in 2‐h post‐challenge glucose. There was no association for fasting glucose.
doi_str_mv 10.1111/dme.12762
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808648650</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3743202571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5952-de0b733b163e2dd051b019c1f29e7a6dc006c0bada49d6e06a6be7e4fa4de9783</originalsourceid><addsrcrecordid>eNqFkc1u1DAURiMEokNhwQsgS2xgkdY_iR2zG4YyVAwtoAJLy7FvJm6dZIgdYLY8OZ5O2wUSwhtvznd8r78se0rwEUnn2HZwRKjg9F42IwUv8rKQ5H42w6KgOcOCHGSPQrjEmFDJ5MPsgJYVqapSzrLfH9ttcEZ7pE10P1zcIh2QRhYijJ3rdR_R0KBGh-j6NdK9RTRv0WYIMTet9h76NaC1n8wQ4FUKbsYhbGDnAmSGdhhjCmmfHgk7UWwBnc2_ni7nF-efURyd9o-zB432AZ7c3IfZl7cnF4t3-ep8ebqYr3JTypLmFnAtGKsJZ0CtxSWpMZGGNFSC0NwajLnBtba6kJYD5prXIKBodGFBioodZi_23jTi9wlCVJ0LBrzXPQxTUKTCFS8qXuL_o1wKSirCaEKf_4VeDtOYNr6mOEmzVzvq5Z4y6XvCCI3ajK7T41YRrHYdqtShuu4wsc9ujFPdgb0jb0tLwPEe-Ok8bP9tUm8-nNwq833ChQi_7hJ6vFJcMFGqb2dL9f4TLRfL10yt2B8Wo7Rt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1696159582</pqid></control><display><type>article</type><title>Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Yates, T. ; Davies, M. J. ; Haffner, S. M. ; Schulte, P. J. ; Thomas, L. ; Huffman, K. M. ; Bales, C. W. ; Preiss, D. ; Califf, R. M. ; Holman, R. R. ; McMurray, J. J. V. ; Bethel, M. A. ; Tuomilehto, J. ; Kraus, W. E.</creator><creatorcontrib>Yates, T. ; Davies, M. J. ; Haffner, S. M. ; Schulte, P. J. ; Thomas, L. ; Huffman, K. M. ; Bales, C. W. ; Preiss, D. ; Califf, R. M. ; Holman, R. R. ; McMurray, J. J. V. ; Bethel, M. A. ; Tuomilehto, J. ; Kraus, W. E.</creatorcontrib><description>Aim To investigate whether previous physical activity levels are associated with blood glucose levels in individuals with impaired glucose tolerance in the context of an international pharmaceutical trial. Methods Data were analysed from the NAVIGATOR trial, which involved 9306 individuals with impaired glucose tolerance and high cardiovascular risk from 40 different countries, recruited in the period 2002–2004. Fasting glucose, 2‐h post‐challenge glucose and physical activity (pedometer) were assessed annually. A longitudinal regression analysis was used to determine whether physical activity levels 2 years (t‐2) and 1 year (t‐1) previously were associated with levels of glucose, after adjusting for previous glucose levels and other patient characteristics. Those participants with four consecutive annual measures of glucose and two consecutive measures of physical activity were included in the analysis. Results The analysis included 3964 individuals. Change in physical activity from t‐2 to t‐1 and activity levels at t‐2 were both associated with 2‐h glucose levels after adjustment for previous glucose levels and baseline characteristics; however, the associations were weak: a 100% increase in physical activity was associated with a 0.9% reduction in 2‐h glucose levels. In addition, previous physical activity only explained an additional 0.05% of the variance in 2‐h glucose over the variance explained by the history of 2‐h glucose alone (R2 = 0.3473 vs. 0.3468). There was no association with fasting glucose. Conclusions In the context of a large international clinical trial, previous physical activity levels did not meaningfully influence glucose levels in those with a high risk of chronic disease, after taking into account participants' previous trajectory of glucose control. What's new? This is the first study to investigate the prospective relationship of daily step count, as measured by a pedometer, with fasting and 2‐h post‐challenge glucose in an international clinical trial. Recent history of physical activity was weakly related to 2‐h glucose in those with a high risk of Type 2 diabetes after taking into account the trajectory of 2‐h glucose established in the preceding 3 years. A 100% increase in daily step count was associated with a 0.9% reduction in 2‐h post‐challenge glucose. There was no association for fasting glucose.</description><identifier>ISSN: 0742-3071</identifier><identifier>EISSN: 1464-5491</identifier><identifier>DOI: 10.1111/dme.12762</identifier><identifier>PMID: 25818859</identifier><identifier>CODEN: DIMEEV</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Accelerometry ; Actigraphy ; Aged ; Angiotensin II Type 1 Receptor Blockers - therapeutic use ; Blood Glucose - metabolism ; Cardiovascular Diseases ; Cohort Studies ; Cyclohexanes - therapeutic use ; Diabetes ; Fasting ; Female ; Glucose Intolerance - drug therapy ; Glucose Intolerance - metabolism ; Glucose Tolerance Test ; Humans ; Hypoglycemic Agents - therapeutic use ; Longitudinal Studies ; Male ; Middle Aged ; Motor Activity ; Phenylalanine - analogs &amp; derivatives ; Phenylalanine - therapeutic use ; Prospective Studies ; Regression Analysis ; Risk Factors ; Risk Reduction Behavior ; Valsartan - therapeutic use</subject><ispartof>Diabetic medicine, 2015-08, Vol.32 (8), p.1090-1096</ispartof><rights>2015 The Authors. Diabetic Medicine © 2015 Diabetes UK</rights><rights>2015 The Authors. Diabetic Medicine © 2015 Diabetes UK.</rights><rights>Diabetic Medicine © 2015 Diabetes UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5952-de0b733b163e2dd051b019c1f29e7a6dc006c0bada49d6e06a6be7e4fa4de9783</citedby><cites>FETCH-LOGICAL-c5952-de0b733b163e2dd051b019c1f29e7a6dc006c0bada49d6e06a6be7e4fa4de9783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25818859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yates, T.</creatorcontrib><creatorcontrib>Davies, M. J.</creatorcontrib><creatorcontrib>Haffner, S. M.</creatorcontrib><creatorcontrib>Schulte, P. J.</creatorcontrib><creatorcontrib>Thomas, L.</creatorcontrib><creatorcontrib>Huffman, K. M.</creatorcontrib><creatorcontrib>Bales, C. W.</creatorcontrib><creatorcontrib>Preiss, D.</creatorcontrib><creatorcontrib>Califf, R. M.</creatorcontrib><creatorcontrib>Holman, R. R.</creatorcontrib><creatorcontrib>McMurray, J. J. V.</creatorcontrib><creatorcontrib>Bethel, M. A.</creatorcontrib><creatorcontrib>Tuomilehto, J.</creatorcontrib><creatorcontrib>Kraus, W. E.</creatorcontrib><title>Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial</title><title>Diabetic medicine</title><addtitle>Diabet. Med</addtitle><description>Aim To investigate whether previous physical activity levels are associated with blood glucose levels in individuals with impaired glucose tolerance in the context of an international pharmaceutical trial. Methods Data were analysed from the NAVIGATOR trial, which involved 9306 individuals with impaired glucose tolerance and high cardiovascular risk from 40 different countries, recruited in the period 2002–2004. Fasting glucose, 2‐h post‐challenge glucose and physical activity (pedometer) were assessed annually. A longitudinal regression analysis was used to determine whether physical activity levels 2 years (t‐2) and 1 year (t‐1) previously were associated with levels of glucose, after adjusting for previous glucose levels and other patient characteristics. Those participants with four consecutive annual measures of glucose and two consecutive measures of physical activity were included in the analysis. Results The analysis included 3964 individuals. Change in physical activity from t‐2 to t‐1 and activity levels at t‐2 were both associated with 2‐h glucose levels after adjustment for previous glucose levels and baseline characteristics; however, the associations were weak: a 100% increase in physical activity was associated with a 0.9% reduction in 2‐h glucose levels. In addition, previous physical activity only explained an additional 0.05% of the variance in 2‐h glucose over the variance explained by the history of 2‐h glucose alone (R2 = 0.3473 vs. 0.3468). There was no association with fasting glucose. Conclusions In the context of a large international clinical trial, previous physical activity levels did not meaningfully influence glucose levels in those with a high risk of chronic disease, after taking into account participants' previous trajectory of glucose control. What's new? This is the first study to investigate the prospective relationship of daily step count, as measured by a pedometer, with fasting and 2‐h post‐challenge glucose in an international clinical trial. Recent history of physical activity was weakly related to 2‐h glucose in those with a high risk of Type 2 diabetes after taking into account the trajectory of 2‐h glucose established in the preceding 3 years. A 100% increase in daily step count was associated with a 0.9% reduction in 2‐h post‐challenge glucose. There was no association for fasting glucose.</description><subject>Accelerometry</subject><subject>Actigraphy</subject><subject>Aged</subject><subject>Angiotensin II Type 1 Receptor Blockers - therapeutic use</subject><subject>Blood Glucose - metabolism</subject><subject>Cardiovascular Diseases</subject><subject>Cohort Studies</subject><subject>Cyclohexanes - therapeutic use</subject><subject>Diabetes</subject><subject>Fasting</subject><subject>Female</subject><subject>Glucose Intolerance - drug therapy</subject><subject>Glucose Intolerance - metabolism</subject><subject>Glucose Tolerance Test</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Motor Activity</subject><subject>Phenylalanine - analogs &amp; derivatives</subject><subject>Phenylalanine - therapeutic use</subject><subject>Prospective Studies</subject><subject>Regression Analysis</subject><subject>Risk Factors</subject><subject>Risk Reduction Behavior</subject><subject>Valsartan - therapeutic use</subject><issn>0742-3071</issn><issn>1464-5491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqFkc1u1DAURiMEokNhwQsgS2xgkdY_iR2zG4YyVAwtoAJLy7FvJm6dZIgdYLY8OZ5O2wUSwhtvznd8r78se0rwEUnn2HZwRKjg9F42IwUv8rKQ5H42w6KgOcOCHGSPQrjEmFDJ5MPsgJYVqapSzrLfH9ttcEZ7pE10P1zcIh2QRhYijJ3rdR_R0KBGh-j6NdK9RTRv0WYIMTet9h76NaC1n8wQ4FUKbsYhbGDnAmSGdhhjCmmfHgk7UWwBnc2_ni7nF-efURyd9o-zB432AZ7c3IfZl7cnF4t3-ep8ebqYr3JTypLmFnAtGKsJZ0CtxSWpMZGGNFSC0NwajLnBtba6kJYD5prXIKBodGFBioodZi_23jTi9wlCVJ0LBrzXPQxTUKTCFS8qXuL_o1wKSirCaEKf_4VeDtOYNr6mOEmzVzvq5Z4y6XvCCI3ajK7T41YRrHYdqtShuu4wsc9ujFPdgb0jb0tLwPEe-Ok8bP9tUm8-nNwq833ChQi_7hJ6vFJcMFGqb2dL9f4TLRfL10yt2B8Wo7Rt</recordid><startdate>201508</startdate><enddate>201508</enddate><creator>Yates, T.</creator><creator>Davies, M. J.</creator><creator>Haffner, S. M.</creator><creator>Schulte, P. J.</creator><creator>Thomas, L.</creator><creator>Huffman, K. M.</creator><creator>Bales, C. W.</creator><creator>Preiss, D.</creator><creator>Califf, R. M.</creator><creator>Holman, R. R.</creator><creator>McMurray, J. J. V.</creator><creator>Bethel, M. A.</creator><creator>Tuomilehto, J.</creator><creator>Kraus, W. E.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201508</creationdate><title>Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial</title><author>Yates, T. ; Davies, M. J. ; Haffner, S. M. ; Schulte, P. J. ; Thomas, L. ; Huffman, K. M. ; Bales, C. W. ; Preiss, D. ; Califf, R. M. ; Holman, R. R. ; McMurray, J. J. V. ; Bethel, M. A. ; Tuomilehto, J. ; Kraus, W. E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5952-de0b733b163e2dd051b019c1f29e7a6dc006c0bada49d6e06a6be7e4fa4de9783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Accelerometry</topic><topic>Actigraphy</topic><topic>Aged</topic><topic>Angiotensin II Type 1 Receptor Blockers - therapeutic use</topic><topic>Blood Glucose - metabolism</topic><topic>Cardiovascular Diseases</topic><topic>Cohort Studies</topic><topic>Cyclohexanes - therapeutic use</topic><topic>Diabetes</topic><topic>Fasting</topic><topic>Female</topic><topic>Glucose Intolerance - drug therapy</topic><topic>Glucose Intolerance - metabolism</topic><topic>Glucose Tolerance Test</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Motor Activity</topic><topic>Phenylalanine - analogs &amp; derivatives</topic><topic>Phenylalanine - therapeutic use</topic><topic>Prospective Studies</topic><topic>Regression Analysis</topic><topic>Risk Factors</topic><topic>Risk Reduction Behavior</topic><topic>Valsartan - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yates, T.</creatorcontrib><creatorcontrib>Davies, M. J.</creatorcontrib><creatorcontrib>Haffner, S. M.</creatorcontrib><creatorcontrib>Schulte, P. J.</creatorcontrib><creatorcontrib>Thomas, L.</creatorcontrib><creatorcontrib>Huffman, K. M.</creatorcontrib><creatorcontrib>Bales, C. W.</creatorcontrib><creatorcontrib>Preiss, D.</creatorcontrib><creatorcontrib>Califf, R. M.</creatorcontrib><creatorcontrib>Holman, R. R.</creatorcontrib><creatorcontrib>McMurray, J. J. V.</creatorcontrib><creatorcontrib>Bethel, M. A.</creatorcontrib><creatorcontrib>Tuomilehto, J.</creatorcontrib><creatorcontrib>Kraus, W. E.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yates, T.</au><au>Davies, M. J.</au><au>Haffner, S. M.</au><au>Schulte, P. J.</au><au>Thomas, L.</au><au>Huffman, K. M.</au><au>Bales, C. W.</au><au>Preiss, D.</au><au>Califf, R. M.</au><au>Holman, R. R.</au><au>McMurray, J. J. V.</au><au>Bethel, M. A.</au><au>Tuomilehto, J.</au><au>Kraus, W. E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial</atitle><jtitle>Diabetic medicine</jtitle><addtitle>Diabet. Med</addtitle><date>2015-08</date><risdate>2015</risdate><volume>32</volume><issue>8</issue><spage>1090</spage><epage>1096</epage><pages>1090-1096</pages><issn>0742-3071</issn><eissn>1464-5491</eissn><coden>DIMEEV</coden><abstract>Aim To investigate whether previous physical activity levels are associated with blood glucose levels in individuals with impaired glucose tolerance in the context of an international pharmaceutical trial. Methods Data were analysed from the NAVIGATOR trial, which involved 9306 individuals with impaired glucose tolerance and high cardiovascular risk from 40 different countries, recruited in the period 2002–2004. Fasting glucose, 2‐h post‐challenge glucose and physical activity (pedometer) were assessed annually. A longitudinal regression analysis was used to determine whether physical activity levels 2 years (t‐2) and 1 year (t‐1) previously were associated with levels of glucose, after adjusting for previous glucose levels and other patient characteristics. Those participants with four consecutive annual measures of glucose and two consecutive measures of physical activity were included in the analysis. Results The analysis included 3964 individuals. Change in physical activity from t‐2 to t‐1 and activity levels at t‐2 were both associated with 2‐h glucose levels after adjustment for previous glucose levels and baseline characteristics; however, the associations were weak: a 100% increase in physical activity was associated with a 0.9% reduction in 2‐h glucose levels. In addition, previous physical activity only explained an additional 0.05% of the variance in 2‐h glucose over the variance explained by the history of 2‐h glucose alone (R2 = 0.3473 vs. 0.3468). There was no association with fasting glucose. Conclusions In the context of a large international clinical trial, previous physical activity levels did not meaningfully influence glucose levels in those with a high risk of chronic disease, after taking into account participants' previous trajectory of glucose control. What's new? This is the first study to investigate the prospective relationship of daily step count, as measured by a pedometer, with fasting and 2‐h post‐challenge glucose in an international clinical trial. Recent history of physical activity was weakly related to 2‐h glucose in those with a high risk of Type 2 diabetes after taking into account the trajectory of 2‐h glucose established in the preceding 3 years. A 100% increase in daily step count was associated with a 0.9% reduction in 2‐h post‐challenge glucose. There was no association for fasting glucose.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>25818859</pmid><doi>10.1111/dme.12762</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0742-3071
ispartof Diabetic medicine, 2015-08, Vol.32 (8), p.1090-1096
issn 0742-3071
1464-5491
language eng
recordid cdi_proquest_miscellaneous_1808648650
source Wiley-Blackwell Read & Publish Collection
subjects Accelerometry
Actigraphy
Aged
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Blood Glucose - metabolism
Cardiovascular Diseases
Cohort Studies
Cyclohexanes - therapeutic use
Diabetes
Fasting
Female
Glucose Intolerance - drug therapy
Glucose Intolerance - metabolism
Glucose Tolerance Test
Humans
Hypoglycemic Agents - therapeutic use
Longitudinal Studies
Male
Middle Aged
Motor Activity
Phenylalanine - analogs & derivatives
Phenylalanine - therapeutic use
Prospective Studies
Regression Analysis
Risk Factors
Risk Reduction Behavior
Valsartan - therapeutic use
title Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T21%3A46%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Physical%20activity%20as%20a%20determinant%20of%20fasting%20and%202-h%20post-challenge%20glucose:%20a%20prospective%20cohort%20analysis%20of%20the%20NAVIGATOR%20trial&rft.jtitle=Diabetic%20medicine&rft.au=Yates,%20T.&rft.date=2015-08&rft.volume=32&rft.issue=8&rft.spage=1090&rft.epage=1096&rft.pages=1090-1096&rft.issn=0742-3071&rft.eissn=1464-5491&rft.coden=DIMEEV&rft_id=info:doi/10.1111/dme.12762&rft_dat=%3Cproquest_cross%3E3743202571%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5952-de0b733b163e2dd051b019c1f29e7a6dc006c0bada49d6e06a6be7e4fa4de9783%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1696159582&rft_id=info:pmid/25818859&rfr_iscdi=true